Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate: A Pilot Observational Study of Feasibility and Acceptability

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00770887

Acronym

SAD

Enrollment

Registered

2008-10-10

Start date

2010-05-31

Completion date

2011-06-30

Last updated

2011-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility

Keywords

Undesired fertility

Brief summary

The purpose of this study is to assess continuation rates and patient satisfaction with self administration subcutaneous depot medroxyprogesterone acetate.

Detailed description

This observational study will include new or current Depo Provera users who express interest in attempting subcutaneous self administration of depot medroxyprogesterone acetate. Candidates will be taught self administration by a clinic assistant at Planned Parenthood of Southwest and Central Florida. Patients who are able to correctly self administer the medication and wish to attempt to continue home self administration, will be provided the supplies and educational materials to do so. Continuation rates and satisfaction with this method will be assessed using preaddressed surveys that patients will return with the above information.

Interventions

PROCEDURESelf administration

Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Women 18 years or older * Can understand written and spoken English * Current or past user of DMPA or desires initiation of DMPA for contraception * Provider has approved DMPA use in this woman * Willing to consider/attempt DMPA self-injection. * Willing to receive phone calls/letter for follow up * Willing to return letters for follow up

Exclusion criteria

Has contraindications to DMPA use: * Vaginal bleeding of unknown etiology * Medication use for Cushing's syndrome * Currently pregnant * Blood pressure \>160/100 * Intolerance to the idea of irregular or absent menses

Design outcomes

Primary

Measure	Time frame
Patient satisfaction with/feasibility of self injection of subcutaneous depot medroxyprogesterone acetate	At onset of trial and every 12 weeks for 1 year

Secondary

Measure	Time frame
Continuation rates of depot medroxyprogesterone acetate among self-injectors	Every 12 weeks for 1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026